Diagnosing and treating gout: A review to aid primary care physicians

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 157-161

  Schlesinger, Naomi ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Gout; Primary care physicians; Rheumatic disorders

Indexed keywords

ALLOPURINOL; COLCHICINE; COLCRYS; CORTICOSTEROID; FEBUXOSTAT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; UNCLASSIFIED DRUG; URATE; ANTIGOUT AGENT; URIC ACID;

ARTHRALGIA; CHRONIC DISEASE; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG METABOLISM; EOSINOPHILIA; GOUT; HUMAN; HYPERURICEMIA; JOINT ASPIRATION; JOINT SWELLING; KIDNEY FAILURE; LOW DRUG DOSE; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; REVIEW; STEVENS JOHNSON SYNDROME; SYNOVIAL FLUID; CASE REPORT; CHEMISTRY; GENERAL PRACTITIONER; MALE; MIDDLE AGED;

ADRENAL CORTEX HORMONES; ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; PHYSICIANS, FAMILY; SYNOVIAL FLUID; URIC ACID;

EID: 77950367264     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2133     Document Type: Review

References (33)

1. Hanly JG, Skedgel C, Sketris I, et al. Gout in the elderly-a population health study. J Rheumatol. 2009;36(4):822-830.
2. Baer PA, Tenenbaum J, Fam AG, Little H. Coexistent septic and crystal arthritis. Report of four cases and literature review. J Rheumatol. 1986;13(3):604-607.
3. Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis. 1970;29(5):461-468.
4. Reginato AJ, Schumacher HR Jr. Crystal-associated arthropathies. Clin Geriatr Med. 1988;4(2):295-322.
5. Schlesinger N. Response to application of ice may help differentiate between gouty arthritis and other inflammatory arthritidies. J Clin Rheumatol. 2006;12(6):275-276.
6. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900.
7. Zhang W, Doherty M, Pascual E, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65(10):1312-1324.
8. Wolfe F, Cathy MA. The misdiagnosis of gout and hyperuricemia. J Rheumatol. 1991;18(8):1232-1234.
9. Schlesinger N, Watson DJ, Norquist JM. Serum urate during acute gout. J Rheumatol. 2009;36(6):1287-1289.
10. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drug. 2004;64(21):2399-2416.
11. Dessein PH, Shipton AE, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59(7):539-543.
12. Schlesinger N, Baker DG, Beutler AM, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2002;29(2):331-334.
13. Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol. 2007;34(7):1566-1568.
14. Schlesinger N, Moore DF, Sun JD, Schumacher HR. A survey of current evaluation and treatment of gout. J Rheumatol. 2006;33(10):2050-2052.
15. US Food and Drug Administration. Colcrys http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation.
16. Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Leading article. Drugs. 2008;68(4):407-415.
17. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008;371(9627):1854-1860.
18. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321-325.
19. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28(3):577-580.
20. Perez-Ruiz F, Calabozo M, Pijoan SI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Care Res. 2002;47(4):356-360.
21. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during antihyperuricemic treatment. Adv Exp Med Biol. 1998;431:13-18.
22. van Lieshout-Zuidema MF, Breedveld FC. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol. 1993;20(8):1383-1385.
23. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol. 1989;16(9);1246-1248.
24. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925-934.
25. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.
26. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545-549.
27. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
28. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial. 2007;20(5):391-395.
29. Halevy S, Ghislain PD, Mockenhaupt M, et al; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32.
30. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47-56.
31. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):646-650.
32. Emmerson BT. The management of gout. N Engl J Med. 1996;334(7):445-451.
33. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742-748.